BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khoruts A, Staley C, Sadowsky MJ. Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology. Nat Rev Gastroenterol Hepatol 2021;18:67-80. [PMID: 32843743 DOI: 10.1038/s41575-020-0350-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Khoruts A. Can FMT Cause or Prevent CRC? Maybe, But There Is More to Consider. Gastroenterology 2021:S0016-5085(21)03230-3. [PMID: 34224741 DOI: 10.1053/j.gastro.2021.06.074] [Reference Citation Analysis]
2 Kumar SB, Arnipalli SR, Ziouzenkova O. Antibiotics in Food Chain: The Consequences for Antibiotic Resistance. Antibiotics (Basel) 2020;9:E688. [PMID: 33066005 DOI: 10.3390/antibiotics9100688] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
3 Nakhi A, Wong HL, Weldy M, Khoruts A, Sadowsky MJ, Dosa PI. Structural modifications that increase gut restriction of bile acid derivatives. RSC Med Chem 2021;12:394-405. [PMID: 34046622 DOI: 10.1039/d0md00425a] [Reference Citation Analysis]
4 Monaghan TM, Duggal NA, Rosati E, Griffin R, Hughes J, Roach B, Yang DY, Wang C, Wong K, Saxinger L, Pučić-Baković M, Vučković F, Klicek F, Lauc G, Tighe P, Mullish BH, Blanco JM, McDonald JAK, Marchesi JR, Xue N, Dottorini T, Acharjee A, Franke A, Li Y, Wong GK, Polytarchou C, Yau TO, Christodoulou N, Hatziapostolou M, Wang M, Russell LA, Kao DH. A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection. Cells 2021;10:3234. [PMID: 34831456 DOI: 10.3390/cells10113234] [Reference Citation Analysis]
5 Mori G, Morrison M, Blumenthal A. Microbiome-immune interactions in tuberculosis. PLoS Pathog 2021;17:e1009377. [PMID: 33857251 DOI: 10.1371/journal.ppat.1009377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Jan N, Hays RA, Oakland DN, Kumar P, Ramakrishnan G, Behm BW, Petri WA Jr, Marie C. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile. mSphere 2021;6:e0066921. [PMID: 34704776 DOI: 10.1128/mSphere.00669-21] [Reference Citation Analysis]
7 Giraud J, Saleh M. Host-Microbiota Interactions in Liver Inflammation and Cancer. Cancers (Basel) 2021;13:4342. [PMID: 34503151 DOI: 10.3390/cancers13174342] [Reference Citation Analysis]
8 Harriman R, Lewis JS. Bioderived materials that disarm the gut mucosal immune system: Potential lessons from commensal microbiota. Acta Biomater 2021:S1742-7061(21)00355-X. [PMID: 34098091 DOI: 10.1016/j.actbio.2021.05.045] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
10 Kociolek LK, Zackular JP, Savidge T. Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations. J Pediatric Infect Dis Soc 2021;10:S8-S15. [PMID: 34791392 DOI: 10.1093/jpids/piab089] [Reference Citation Analysis]
11 Schmidt C, Grunert PC, Stallmach A. An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective. Front Pharmacol 2021;12:655054. [PMID: 33912062 DOI: 10.3389/fphar.2021.655054] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]
13 Gogokhia L, Round JL. Immune-bacteriophage interactions in inflammatory bowel diseases. Curr Opin Virol 2021;49:30-5. [PMID: 34029992 DOI: 10.1016/j.coviro.2021.04.010] [Reference Citation Analysis]
14 Benech N, Sokol H. Expert centres for faecal microbiota transplantation: The guarantee for safe and effective use of faecal transplants. United European Gastroenterol J 2020;8:1145-6. [PMID: 33167783 DOI: 10.1177/2050640620970372] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Matson V, Chervin CS, Gajewski TF. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology 2021;160:600-13. [PMID: 33253684 DOI: 10.1053/j.gastro.2020.11.041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
16 Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdecha S, Janvilisri T. Frontiers in antibiotic alternatives for Clostridioides difficile infection. World J Gastroenterol 2021; 27(42): 7210-7232 [PMID: 34876784 DOI: 10.3748/wjg.v27.i42.7210] [Reference Citation Analysis]
17 Mercer DK, Francis ML, Fraser-Pitt D. Antimicrobial immunotherapeutics: past, present and future. Emerg Top Life Sci 2021:ETLS20200348. [PMID: 34196722 DOI: 10.1042/ETLS20200348] [Reference Citation Analysis]